Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.
JOURNAL OF CLINICAL ONCOLOGY(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF CLINICAL ONCOLOGY(2022)